Structure Therapeutics announces aleniglipron trial presentations at ObesityWeek 2026
GPCR•Structure Therapeutics will present research on aleniglipron obesity trials at ObesityWeek on Nov. 15, 2026, in National Harbor, Maryland. Two posters will cover dose-ranging effects in the ACCESS trials and an open-label extension.
1. Trial presentations
Structure Therapeutics will present aleniglipron obesity trial research at ObesityWeek on Nov. 15, 2026, in National Harbor, Maryland. The two posters will cover the ACCESS trials’ dose-ranging effects and an open-label extension in participants with overweight or obesity. Aleniglipron is an investigational, once-daily oral small-molecule GLP-1 receptor agonist being developed for chronic weight management.
